- Ticker
- ACAD
- Price
- 18.57
- Stock movement down
- -0.09 (-0.48%)
- Company name
- ACADIA Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 3.01B
- Ent værdi
- 3.03B
- Pris/omsætning
- 5.88
- Pris/bog
- 7.06
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -
- Efterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -
- 1 års afkast
- -15.32%
- 3 års afkast
- -23.54%
- 5 års afkast
- -9.55%
- 10 års afkast
- 12.21%
Senest opdateret: 2023-01-27
UDBYTTE
ACAD betaler ikke udbytte
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | 5.88 |
| Pris til egenkapital | 7.06 |
| EV i forhold til salg | 5.92 |
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 161.93M |
| EPS (TTM) | -1.34 |
| FCF pr. aktie (TTM) | -0.70 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 511.50M |
| Bruttofortjeneste (TTM) | 501.19M |
| Driftsindkomst (TTM) | -222.19M |
| Nettoindkomst (TTM) | -217.34M |
| EPS (TTM) | -1.34 |
| EPS (1 år frem) | -0.78 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 97.98% |
| Driftsmargin (TTM) | -43.44% |
| Fortjenstmargin (TTM) | -42.49% |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 154.84M |
| Nettotilgodehavender | 56.14M |
| Omsætningsaktiver i alt | 521.55M |
| Goodwill | 0.00 |
| Immaterielle aktiver | 0.00 |
| Ejendomme, anlæg og udstyr | 0.00 |
| Sum aktiver | 602.49M |
| Kreditor | 10.01M |
| Kortfristet/nuværende langsigtet gæld | 63.00M |
| Summen af kortfristede forpligtelser | 116.57M |
| Sum gæld | 176.81M |
| Aktionærernes egenkapital | 425.69M |
| Materielle nettoaktiver | 425.69M |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | -113.30M |
| Investeringsudgifter (TTM) | 1.00K |
| Fri pengestrøm (TTM) | -113.30M |
| Udbetalt udbytte (TTM) | 0.00 |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | -51.06% |
| Afkast af aktiver | -36.07% |
| Afkast af investeret kapital | -49.97% |
| Kontant afkast af investeret kapital | -26.05% |
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 18.57 |
| Daglig høj | 18.77 |
| Daglig lav | 18.39 |
| Daglig volumen | 921K |
| Højeste gennem alle tider | 57.00 |
| 1 års analytiker estimat | 18.47 |
| Beta | 0.59 |
| EPS (TTM) | -1.34 |
| Udbytte pr. aktie | - |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | 27 Feb 2023 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| ACAD | S&P500 | |
| Nuværende prisfald fra top notering | -67.42% | -15.08% |
| Højeste prisfald | -96.29% | -56.47% |
| Højeste efterår dato | 12 Nov 2010 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -47.90% | -11.49% |
| Gennemsnitlig tid til nyt højdepunkt | 51 days | 13 days |
| Maks. tid til nyt højdepunkt | 1820 days | 1805 days |
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
3.01B
Markedsværdi kategori
Mid-cap
Beskrivelse
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Personale
510
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Stephen R. Davis
Land
USA
By
San Diego
Aktietype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
SAN DIEGO, January 09, 2023--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the appointment of Dr. Doug Williamson as Executive Vice President, Head of Research and Development (R&D). Dr. ...
9. januar 2023
Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have been...
3. januar 2023
SAN DIEGO, January 03, 2023--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the journal Drug Safety published results from a retrospective analysis finding a lower mortality risk in p...
3. januar 2023
Acadia Pharmaceuticals is working to develop novel RNA-based medicines for the treatment of severe and rare genetic diseases of the central nervous system. The On-Balance-Volume (OBV) line has weake...
3. januar 2023
SAN DIEGO, December 21, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:00...
21. december 2022
SAN DIEGO, November 08, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:
8. november 2022
Acadia (ACAD) reports a narrower-than-expected loss in the third quarter of 2022 while revenues fall shy of estimates. Tightens guidance for Nuplazid.
3. november 2022
Acadia (ACAD) delivered earnings and revenue surprises of 5.56% and 6.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
2. november 2022
SAN DIEGO, November 02, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2022.
2. november 2022
Acadia Pharmaceuticals (ACAD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
1. november 2022
Næste side